AbbVie had a strong Q1 performance in its oncology, neuroscience, and immunology franchises. Read why I continue to rate ABBV stock with a Strong Buy rating.
Why AbbVie’s Stock Is A Strong Buy After Q1 2025 Results
view original post
AbbVie had a strong Q1 performance in its oncology, neuroscience, and immunology franchises. Read why I continue to rate ABBV stock with a Strong Buy rating.